These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25444820)

  • 1. Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia.
    Deshmukh AA; Chiao EY; Das P; Cantor SB
    Vaccine; 2014 Dec; 32(51):6941-6947. PubMed ID: 25444820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men.
    Deshmukh AA; Chhatwal J; Chiao EY; Nyitray AG; Das P; Cantor SB
    Clin Infect Dis; 2015 Nov; 61(10):1527-35. PubMed ID: 26223993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness.
    Deshmukh AA; Chiao EY; Cantor SB; Stier EA; Goldstone SE; Nyitray AG; Wilkin T; Wang X; Chhatwal J
    Cancer; 2017 Dec; 123(23):4709-4719. PubMed ID: 28950043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study.
    Swedish KA; Factor SH; Goldstone SE
    Clin Infect Dis; 2012 Apr; 54(7):891-8. PubMed ID: 22291111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now.
    Deshmukh AA; Cantor SB; Fenwick E; Chiao EY; Nyitray AG; Stier EA; Goldstone SE; Wilkin T; Chhatwal J
    Vaccine; 2017 Sep; 35(38):5102-5109. PubMed ID: 28807605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.
    Palefsky JM; Giuliano AR; Goldstone S; Moreira ED; Aranda C; Jessen H; Hillman R; Ferris D; Coutlee F; Stoler MH; Marshall JB; Radley D; Vuocolo S; Haupt RM; Guris D; Garner EI
    N Engl J Med; 2011 Oct; 365(17):1576-85. PubMed ID: 22029979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM.
    Gosens KCM; van der Zee RP; van Heukelom MLS; Jongen VW; Cairo I; van Eeden A; van Noesel CJM; Quint WGV; Pasmans H; Dijkgraaf MGW; de Vries HJC; Prins JM
    AIDS; 2021 Sep; 35(11):1753-1764. PubMed ID: 33966029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine.
    Wilkin T; Lee JY; Lensing SY; Stier EA; Goldstone SE; Berry MJ; Jay N; Aboulafia DM; Einstein MH; Saah A; Mitsuyasu RT; Palefsky JM
    HIV Clin Trials; 2013; 14(2):75-9. PubMed ID: 23611828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost-effectiveness of human papillomavirus vaccination strategies among men who have sex with men in China: a modeling study.
    Li Y; Lin YF; Wu X; Zhou X; Tian T; Guo Z; Fu L; Yang L; Lu Z; Fan S; Lu Y; Ke W; Zou H
    Front Immunol; 2023; 14():1197191. PubMed ID: 37426648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years.
    Hidalgo-Tenorio C; Pasquau J; Omar-Mohamed M; Sampedro A; López-Ruz MA; López Hidalgo J; Ramírez-Taboada J
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33498165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Prevalence of Anal High-Grade Squamous Intraepithelial Lesions, and Prevention Through Human Papillomavirus Vaccination, in Young Men Who Have Sex With Men Living With Human Immunodeficiency Virus.
    Palefsky JM; Lensing SY; Belzer M; Lee J; Gaur AH; Mayer K; Futterman D; Stier EA; Paul ME; Chiao EY; Reirden D; Goldstone SE; Tirado M; Cachay ER; Barroso LF; Da Costa M; Darragh TM; Rudy BJ; Wilson CM; Kahn JA
    Clin Infect Dis; 2021 Oct; 73(8):1388-1396. PubMed ID: 33991185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men.
    Sahasrabuddhe VV; Castle PE; Follansbee S; Borgonovo S; Tokugawa D; Schwartz LM; Lorey TS; LaMere BJ; Gage JC; Fetterman B; Boyle S; Sadorra M; Tang SD; Darragh TM; Wentzensen N
    J Infect Dis; 2013 Feb; 207(3):392-401. PubMed ID: 23162133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.
    Kim JJ
    Lancet Infect Dis; 2010 Dec; 10(12):845-52. PubMed ID: 21051295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
    Hidalgo-Tenorio C; Ramírez-Taboada J; Gil-Anguita C; Esquivias J; Omar-Mohamed-Balgahata M; SamPedro A; Lopez-Ruz M; Pasquau J
    AIDS Res Ther; 2017 Jul; 14(1):34. PubMed ID: 28720147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Inquiry: Does qHPV vaccine prevent anal intraepithelial neoplasia and condylomata in men?
    Shum J; Kelsberg G; Safranek S
    J Fam Pract; 2015 Sep; 64(9):581-3. PubMed ID: 26546954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of surveillance strategies after treatment for high-grade anal dysplasia in high-risk patients.
    Assoumou SA; Mayer KH; Panther L; Linas BP; Kim J
    Sex Transm Dis; 2013 Apr; 40(4):298-303. PubMed ID: 23486494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Study of HPV Vaccination as a Primary Prevention Strategy for Anal Cancer in HIV-Positive Men in Chile.
    Vargas Parada C; Lennert Veerman J
    Value Health Reg Issues; 2016 Dec; 11():17-23. PubMed ID: 27986194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic HPV vaccination and anal cancer.
    Stier EA; Chigurupati NL; Fung L
    Hum Vaccin Immunother; 2016 Jun; 12(6):1348-51. PubMed ID: 26933898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.